Skf-89124A

Skf-89124A

SCHEMBL2914813

CCCN(CCC)CCc1ccc(O)c2c1CC(=O)N2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 12/20 1.00
DRD1 P21728 3/20 1.00
DRD4 P21917 3/20 1.00
DRD5 P21918 3/20 1.00
DRD3 P35462 3/20 1.00
HTR1A P08908 2/20 0.61
KDM4E B2RXH2 1/20 0.61
LMNA P02545 1/20 0.61
CHRM2 P08172 1/20 0.61
CYP3A4 P08684 1/20 0.61
ADRA2A P08913 1/20 0.61
CYP2D6 P10635 1/20 0.61
CYP2C9 P11712 1/20 0.61
ADRA2B P18089 1/20 0.61
HTR2A P28223 1/20 0.61
MAPK1 P28482 1/20 0.61
CYP2C19 P33261 1/20 0.61
ADRA1A P35348 1/20 0.61
HRH1 P35367 1/20 0.61
OPRM1 P35372 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Skf-89124A SCHEMBL7382070 0.99 DRD2 (0.97) DRD2DRD1DRD4DRD5DRD3
Hydrochloric Acid SCHEMBL7374216 0.94 DRD2 (0.88) DRD2DRD1DRD4DRD5DRD3
SCHEMBL10921043 0.82 DRD2 (0.70) DRD2DRD1DRD4DRD5DRD3
SCHEMBL10920726 0.82 DRD2 (0.70) DRD2DRD1DRD4DRD5DRD3
Hydrochloric Acid SCHEMBL7379885 0.81 DRD2 (0.68) DRD2DRD1DRD4DRD5DRD3
Bromide SCHEMBL10920638 0.81 DRD2 (0.68) DRD2DRD1DRD4DRD5DRD3
Bromide SCHEMBL10919553 0.81 DRD2 (0.68) DRD2DRD1DRD4DRD5DRD3
Bromide SCHEMBL7380398 0.79 DRD2 (0.65) DRD2DRD1DRD4DRD5DRD3
SCHEMBL7383689 0.79 DRD2 (0.65) DRD2DRD1DRD4DRD5DRD3
Bromide SCHEMBL7384529 0.78 DRD2 (0.64) DRD2DRD1DRD4DRD5DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0046666-B1 2(3H)-INDOLONES, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM SMITHKLINE BECKMAN CORPORATION (US) 1986-04-23 EP claimed
US-4414224-A 4-AMINO OR SUBSTITUTED AMINO-7-HYDROXY-2-(3H)-INDOLONES SMITHKLINE BECKMAN CORPORATION (US) 1983-11-08 US claimed
EP-0046666-A1 2(3H)-indolones, process for their preparation and compositions containing them SMITHKLINE BECKMAN CORPORATION (US) 1982-03-03 EP claimed
US-4314944-A CARDIOVASCULAR DISORDERS, HYPOTENSIVE AGENTS SMITHKLINE CORPORATION (US) 1982-02-09 US claimed
EP-1385857-B1 PHARMACEUTICAL DOPAMINE GLYCOCONJUGATE COMPOSITIONS AND METHODS OF THEIR PREPARATION INTERNAT MEDICAL INNOVATIONS I (US) 2010-08-25 EP disclosed
US-7378439-B2 Process for the preparation of 4-(2-dipropylaminoethyl)-1,3-dihydro-2H-indol-2-one hydrochloride USV, LTD. (IN) 2008-05-27 US disclosed
US-7378439-B2 Process for the preparation of 4-(2-dipropylaminoethyl)-1,3-dihydro-2H-indol-2-one hydrochloride USV, LTD. (IN) 2008-05-27 US disclosed
US-20060189547-A1 Novel pharmaceutical agents containing carbohydrate moieties and methods of their preparation and use CHRISTIAN SAMUEL T 2006-08-24 US disclosed
US-20030119761-A1 Novel pharmaceutical agents containing carbohydrate moieties and methods of their preparation and use CHRISTIAN SAMUEL T (US) 2003-06-26 US disclosed
US-4663482-A Intermediates for preparing 7-(2-aminoethyl)-1,3-benzthia- or oxa- zol-2(3H)-ones SMITHKLINE BECKMAN CORPORATION (US) 1987-05-05 US disclosed
EP-0046666-B1 2(3H)-INDOLONES, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM SMITHKLINE BECKMAN CORPORATION (US) 1986-04-23 EP disclosed
EP-0174811-A2 7-(2-aminoethyl)-1,3-Benzthia- or oxa- zol-2(3H) -ones SMITHKLINE BECKMAN CORPORATION (US) 1986-03-19 EP disclosed
US-4554284-A 7-(2-Aminoethyl)-1,3-benzthia- or oxa-zol-2(3H)-ones SMITHKLINE BECKMAN CORPORATION (US) 1985-11-19 US disclosed
US-4414224-A 4-AMINO OR SUBSTITUTED AMINO-7-HYDROXY-2-(3H)-INDOLONES SMITHKLINE BECKMAN CORPORATION (US) 1983-11-08 US disclosed
US-4414224-A 4-AMINO OR SUBSTITUTED AMINO-7-HYDROXY-2-(3H)-INDOLONES SMITHKLINE BECKMAN CORPORATION (US) 1983-11-08 US disclosed
EP-0046666-A1 2(3H)-indolones, process for their preparation and compositions containing them SMITHKLINE BECKMAN CORPORATION (US) 1982-03-03 EP disclosed
EP-0046666-A1 2(3H)-indolones, process for their preparation and compositions containing them SMITHKLINE BECKMAN CORPORATION (US) 1982-03-03 EP disclosed
US-4314944-A CARDIOVASCULAR DISORDERS, HYPOTENSIVE AGENTS SMITHKLINE CORPORATION (US) 1982-02-09 US disclosed
US-4314944-A CARDIOVASCULAR DISORDERS, HYPOTENSIVE AGENTS SMITHKLINE CORPORATION (US) 1982-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030119761-A1 Novel pharmaceutical agents containing carbohydrate moieties and methods of their preparation and use CSGALNACT1, DDOST, STT3B DRD2 694/4885DRD1 711/4885DRD4 729/4885
US-20060189547-A1 Novel pharmaceutical agents containing carbohydrate moieties and methods of their preparation and use CSGALNACT1, DDOST, STT3B DRD2 694/4885DRD1 711/4885DRD4 729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.